TECNZ Stock Overview
Provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for TECNZ from our risk checks.
Tecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 214.00 |
| 52 Week High | CHF 391.90 |
| 52 Week Low | CHF 206.40 |
| Beta | 0.70 |
| 11 Month Change | -3.69% |
| 3 Month Change | -25.17% |
| 1 Year Change | -30.79% |
| 33 Year Change | -60.95% |
| 5 Year Change | n/a |
| Change since IPO | 209.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| TECNZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 2.4% | 4.4% | 2.2% |
| 1Y | -30.8% | -27.5% | 8.8% |
Return vs Industry: TECNZ matched the UK Life Sciences industry which returned -30% over the past year.
Return vs Market: TECNZ underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| TECNZ volatility | |
|---|---|
| TECNZ Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: TECNZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: TECNZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,000 | Achim von Leoprechting | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution.
Tecan Group AG Fundamentals Summary
| TECNZ fundamental statistics | |
|---|---|
| Market cap | CHF 2.75b |
| Earnings (TTM) | CHF 101.34m |
| Revenue (TTM) | CHF 1.00b |
27.1x
P/E Ratio2.7x
P/S RatioIs TECNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 1.00b |
| Cost of Revenue | CHF 653.34m |
| Gross Profit | CHF 346.71m |
| Other Expenses | CHF 245.37m |
| Earnings | CHF 101.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 12, 2025
| Earnings per share (EPS) | 7.90 |
| Gross Margin | 34.67% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 17.8% |
How did TECNZ perform over the long term?
See historical performance and comparison